Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Relay Therapeutics (RLAY) Shares Outstanding (Weighted Average) (2020 - 2025)

Historic Shares Outstanding (Weighted Average) for Relay Therapeutics (RLAY) over the last 6 years, with Q3 2025 value amounting to $172.4 million.

  • Relay Therapeutics' Shares Outstanding (Weighted Average) rose 2293.4% to $172.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $172.4 million, marking a year-over-year increase of 2293.4%. This contributed to the annual value of $142.9 million for FY2024, which is 1655.4% up from last year.
  • Per Relay Therapeutics' latest filing, its Shares Outstanding (Weighted Average) stood at $172.4 million for Q3 2025, which was up 2293.4% from $171.3 million recorded in Q2 2025.
  • Relay Therapeutics' Shares Outstanding (Weighted Average)'s 5-year high stood at $172.4 million during Q3 2025, with a 5-year trough of $90.2 million in Q1 2021.
  • Over the past 5 years, Relay Therapeutics' median Shares Outstanding (Weighted Average) value was $121.7 million (recorded in 2023), while the average stood at $124.1 million.
  • Per our database at Business Quant, Relay Therapeutics' Shares Outstanding (Weighted Average) skyrocketed by 207145.2% in 2021 and then skyrocketed by 784.87% in 2024.
  • Relay Therapeutics' Shares Outstanding (Weighted Average) (Quarter) stood at $95.1 million in 2021, then grew by 17.97% to $112.2 million in 2022, then grew by 9.22% to $122.6 million in 2023, then grew by 16.55% to $142.9 million in 2024, then rose by 20.66% to $172.4 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $172.4 million in Q3 2025, compared to $171.3 million in Q2 2025 and $169.2 million in Q1 2025.